Table 2.
Baseline characteristics of the study population
| End-stage renal disease | Population Controls | P | |
|---|---|---|---|
| Number of participants |
12,293 |
229,524 |
- |
| Male sex, n (%) |
7,683 (62.5) |
143,622 (62.6) |
0.9 |
| Age at indexdatea, n (%) |
|
|
|
| 14-49 |
3,516 (28.6) |
64,464 (28.1) |
0.5 |
| 50-64 |
3,630 (29.5) |
68,413 (29.8) |
|
| ≥65 |
5,147 (41.9) |
96,647 (42.1) |
|
| Comorbidity level at indexdateb |
|
|
|
| Low |
4,231 (34.4) |
169,330 (73.8) |
<0.001 |
| Medium |
3,663 (29.8) |
46,539 (20.3) |
|
| High |
4,399 (35.8) |
13,655 (6.0) |
|
| Cause of end-stage renal disease |
|
|
|
| Glomerulonephritis |
1,751 (14.2) |
- |
NA |
| Diabetes I + II |
2,595 (21.1) |
- |
|
| Chronic interstitial nephritis |
1,496 (12.2) |
- |
|
| Hypertension and Chronic renal |
|
|
|
| failure without specification |
4,019 (32.7) |
- |
|
| Adult polycystic kidney disease |
969 (7.9) |
- |
|
| Vasculitis |
438 (3.6) |
- |
|
| Other |
1,025 (8.3) |
- |
|
| Transplant history |
|
|
|
| No transplantation |
8,978 (73.0) |
- |
NA |
| ≥1 Transplantation | 3,315 (27.0) | - |
aIndexdate: Date of first treatment for end-stage renal disease and date of sampling for controls.
bThree levels of comorbidity was created based on Charlson comorbidity index score (CCI) at the date of first treatment with renal replacement therapy “Low” (CCI = 0), “Medium” CCI 1–2, and “High” CCI > 2. Renal diagnosis was not included in the CCI score in this study.